Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EVGP | ISIN: US89237H3084 | Ticker-Symbol: N/A
Berlin
02.07.24
08:26 Uhr
1,410 Euro
0,000
0,00 %
1-Jahres-Chart  (nicht börsennotiert)
TRACON PHARMACEUTICALS INC Chart 1 Jahr

Aktuelle News zur TRACON PHARMACEUTICALS

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.11.24Tracon Pharmaceuticals, Inc. - 15-12G, Securities registration termination5
30.07.24TRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Announces it Will Wind Down Operations288SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (OTCQB: TCON) today announced that the Company has terminated its employees and will wind down its operations. This decision was...
► Artikel lesen
16.07.24Delisting of Securities of CONX Corp.; Priveterra Acquisition Corp. II; Yield10 Bioscience, Inc.; Aesthetic Medical International Holdings Group; Breeze Holdings Acquisition Corp.; Quadro Acquisition One Corp.; DermTech, Inc.; TRACON Pharmaceuticals ...333NEW YORK, July 16, 2024 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock, units, and warrants of CONX Corp. CONX Corp.'s securities were suspended on...
► Artikel lesen
TRACON PHARMACEUTICALS Aktie jetzt für 0€ handeln
01.07.24TRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform198The objective response rate by blinded independent central review in the fully enrolled ENVASARC pivotal trial in the 82 evaluable patients is 5% (four responders) and did not meet the primary endpoint...
► Artikel lesen
11.06.24TRACON Pharmaceuticals, Inc.: TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients207Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam Radiotherapy...
► Artikel lesen
14.05.24TRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update213SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development...
► Artikel lesen
6 Nachrichten in den letzten 12 Monaten